A Phase 3 interventional study of Acetazolamide and Metolazone 2.5 MG in Acute Heart Failure, sponsored by Johannes Grand. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Johannes Grand · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.
Among the 14 studies testing acetazolamide in Heart Failure, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2024, is one of 3 in phase 3, and was the 8th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Universitas Diponegoro · Sites in Indonesia
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Lucrecia Maria Burgos
Ages 18+
Clinica Alemana de Santiago
Ages 18+
By country, each count listing its studies:
Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 939 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Johannes Grand is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Johannes Grand has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies testing acetazolamide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593612Lucrecia Maria BurgosTACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure | 2027-01-15 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT06273397Clinica Alemana de SantiagoAcetazolamide or Metolazone in Acute Heart Failure | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing acetazolamide in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial aims to identify the best strategy for treating acute heart failure (AHF) with volume overload in patients at risk of diuretic resistance. It is a double-blinded, randomized, controlled, multicenter study comparing loop-diuretics combined with metolazone, loop-diuretics combined with acetazolamide, and loop-diuretics with matching placebos.
Eligible participants are adults aged 18 years or older who are hospitalized with AHF and have clinical signs of congestion and a risk of diuretic resistance.
The primary outcome is the number of days alive and out of hospital through day 30. Secondary outcomes are clinical benefit at 30 days, assessed using a hierarchical win ratio; days alive and out of hospital through day 90; and the duration of the index hospital admission.
The trial aims to enroll 939 participants across three treatment arms (313 per arm). The sample size is based on detecting a clinically relevant between-group difference of two days alive and out of hospital through day 30, with 80% power and adjustment for comparisons between the three groups.
Intravenous loop diuretics remain the cornerstone of treatment for acute heart failure with volume overload. However, a substantial proportion of patients experience an insufficient diuretic response, which may contribute to persistent congestion, prolonged hospitalization, and adverse clinical outcomes. Diuretic resistance may arise from several mechanisms, including reduced delivery of diuretics to their site of action, impaired renal function, and compensatory sodium reabsorption in nephron segments not targeted by loop diuretics.
Sequential nephron blockade represents a potential strategy to overcome diuretic resistance by combining diuretics acting at different sites of the nephron. Acetazolamide inhibits carbonic anhydrase in the proximal tubule, thereby reducing proximal sodium bicarbonate reabsorption and increasing sodium delivery to downstream nephron segments. Metolazone is a thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, potentially counteracting compensatory distal sodium reabsorption during loop diuretic treatment.
Although both approaches may enhance natriuresis and facilitate decongestion, they differ in their mechanisms of action, electrolyte effects, and potential adverse events. Direct randomized comparisons of these strategies in patients hospitalized with acute heart failure are limited, and uncertainty remains regarding their relative clinical effectiveness and safety.
This trial is designed to address this evidence gap by directly comparing proximal and distal tubular diuretic strategies as adjuncts to intravenous loop diuretic therapy. The findings may help establish the optimal pharmacological approach to decongestion in patients with acute heart failure who are at risk of diuretic resistance.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Display risk of diuretic resistance, characterized by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetazolamide 500 mg IV at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-metolazone tablet at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Drug: Acetazolamide
Metolazone 2.5 mg orally at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-acetazolamide injection at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Drug: Metolazone 2.5 MG
Matching placebo-acetazolamide injection and placebo-metolazone tablet at randomization (day 0) and on the next three mornings (days 1, 2 and 3), in addition to usual care with loop-diuretics (SGLT2 inhibitors are allowed). The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Other: Double-placebo
Acetazolamide 500 mg IV at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-metolazone tablet at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Metolazone 2.5 mg orally at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-acetazolamide injection at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Matching placebo-acetazolamide injection and placebo-metolazone tablet at randomization (day 0) and on the next three mornings (days 1, 2 and 3), in addition to usual care with loop-diuretics (SGLT2 inhibitors are allowed). The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.
Days alive and out of hospital through day 30
Number of days alive and out of hospital during the 30-day period from inclusion. A return visit to the emergency department with discharge on the same day counts as one day in hospital.
Time frame: 30 days
Clinical benefit at 30 days assessed using a hierarchical win ratio
Clinical benefit at 30 days, consisting of all-cause death, readmission after discharge from the index hospitalization, new receipt of renal replacement therapy, or persistent renal dysfunction (final inpatient creatinine ≥200% of baseline), assessed using a hierarchical win-ratio approach.
Time frame: 30 days
Days alive and out of hospital through day 90
Number of days alive and out of hospital from inclusion through day 90.
Time frame: 90 days
Duration of the index hospital admission
Number of days admitted during the index hospital admission.
Time frame: From index hospital admission until discharge, assessed up to 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Mar 2028, 41 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 41 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2027 → Mar 2028 and completion Dec 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetazolamide · Metolazone
Johannes Grand